Daewon Pharmaceutical's Newvein, a Venous Circulation Enhancer, Relaunched with Improved Consumer Convenience

Daewon Pharmaceutical Venous Circulation Improvement Agent Newvein. Photo by Daewon Pharmaceutical

Daewon Pharmaceutical announced on the 17th that its chewable venous and lymphatic circulation improvement product, 'Newvein AC,' has undergone a complete brand renewal, including a package design change and the launch of a new specification.

Newvein AC is an over-the-counter drug with 3500 mg of troxerutin as its main ingredient. It can help relieve swelling and pain caused by venous and lymphatic circulation disorders such as varicose veins and restless legs syndrome. Troxerutin is a flavonoid compound derived from the pagoda tree.

The existing Newvein AC consisted of two types of products: a single product with a 14-stick package and a 28-stick specification product containing two 14-stick packages. With the new release of a 7-stick package, the 14-stick package has been replaced by the 7-stick package, and the 28-stick specification product has been reorganized to consist of four 7-stick packages.

This renewal is based on the results of Daewon Pharmaceutical's independently conducted '2024 Venous Circulation Drug Consumer Survey.' In the survey, 74.7% of respondents answered that the effect of Newvein AC appears 'within 7 days,' and reflecting this consumer feedback, the 7-stick package was newly launched.

The package design was also changed to be more intuitive. The stick pouch image is prominently displayed on the front to emphasize that it is an easy-to-take and portable stick-type pouch product.

A Daewon Pharmaceutical official stated, "We renewed the product to increase consumer accessibility and facilitate pharmacist consultations," adding, "We recommend the 28-stick configuration for consumers who want long-term use."

This content was produced with the assistance of AI translation services.